Editor’s highlights from Future Oncology – November 2020

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues! Check out Louis’ highlights below: Trastuzumab emtansine (T-DM1): A game-changer in human epidermal growth factor-2 (Her2)-positive early breast cancer Breast cancer is a diverse form of cancer where many factors have been found to control the aggressiveness of tumors and the response or resistance to treatment. The prevalence of breast cancer in the population and the significant amount of funding the disease receives means patients can benefit from treatments that target many of...